First Time Loading...

MeiraGTx Holdings PLC
NASDAQ:MGTX

Watchlist Manager
MeiraGTx Holdings PLC Logo
MeiraGTx Holdings PLC
NASDAQ:MGTX
Watchlist
Price: 4.71 USD -3.09% Market Closed
Updated: Apr 26, 2024

Intrinsic Value

MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. [ Read More ]

The intrinsic value of one MGTX stock under the Base Case scenario is 45.8 USD. Compared to the current market price of 4.71 USD, MeiraGTx Holdings PLC is Undervalued by 90%.

Key Points:
MGTX Intrinsic Value
Base Case
45.8 USD
Undervaluation 90%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
MeiraGTx Holdings PLC

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling MGTX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
MeiraGTx Holdings PLC

Provide an overview of the primary business activities
of MeiraGTx Holdings PLC.

What unique competitive advantages
does MeiraGTx Holdings PLC hold over its rivals?

What risks and challenges
does MeiraGTx Holdings PLC face in the near future?

Has there been any significant insider trading activity
in MeiraGTx Holdings PLC recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for MeiraGTx Holdings PLC.

Provide P/S
for MeiraGTx Holdings PLC.

Provide P/E
for MeiraGTx Holdings PLC.

Provide P/OCF
for MeiraGTx Holdings PLC.

Provide P/FCFE
for MeiraGTx Holdings PLC.

Provide P/B
for MeiraGTx Holdings PLC.

Provide EV/S
for MeiraGTx Holdings PLC.

Provide EV/GP
for MeiraGTx Holdings PLC.

Provide EV/EBITDA
for MeiraGTx Holdings PLC.

Provide EV/EBIT
for MeiraGTx Holdings PLC.

Provide EV/OCF
for MeiraGTx Holdings PLC.

Provide EV/FCFF
for MeiraGTx Holdings PLC.

Provide EV/IC
for MeiraGTx Holdings PLC.

Show me price targets
for MeiraGTx Holdings PLC made by professional analysts.

What are the Revenue projections
for MeiraGTx Holdings PLC?

How accurate were the past Revenue estimates
for MeiraGTx Holdings PLC?

What are the Net Income projections
for MeiraGTx Holdings PLC?

How accurate were the past Net Income estimates
for MeiraGTx Holdings PLC?

What are the EPS projections
for MeiraGTx Holdings PLC?

How accurate were the past EPS estimates
for MeiraGTx Holdings PLC?

What are the EBIT projections
for MeiraGTx Holdings PLC?

How accurate were the past EBIT estimates
for MeiraGTx Holdings PLC?

Compare the revenue forecasts
for MeiraGTx Holdings PLC with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of MeiraGTx Holdings PLC and its key competitors using the latest financial data.

Compare historical revenue growth rates
of MeiraGTx Holdings PLC against its competitors.

Analyze the profit margins
(gross, operating, and net) of MeiraGTx Holdings PLC compared to its peers.

Compare the P/E ratios
of MeiraGTx Holdings PLC against its peers.

Discuss the investment returns and shareholder value creation
comparing MeiraGTx Holdings PLC with its peers.

Analyze the financial leverage
of MeiraGTx Holdings PLC compared to its main competitors.

Show all profitability ratios
for MeiraGTx Holdings PLC.

Provide ROE
for MeiraGTx Holdings PLC.

Provide ROA
for MeiraGTx Holdings PLC.

Provide ROIC
for MeiraGTx Holdings PLC.

Provide ROCE
for MeiraGTx Holdings PLC.

Provide Gross Margin
for MeiraGTx Holdings PLC.

Provide Operating Margin
for MeiraGTx Holdings PLC.

Provide Net Margin
for MeiraGTx Holdings PLC.

Provide FCF Margin
for MeiraGTx Holdings PLC.

Show all solvency ratios
for MeiraGTx Holdings PLC.

Provide D/E Ratio
for MeiraGTx Holdings PLC.

Provide D/A Ratio
for MeiraGTx Holdings PLC.

Provide Interest Coverage Ratio
for MeiraGTx Holdings PLC.

Provide Altman Z-Score Ratio
for MeiraGTx Holdings PLC.

Provide Quick Ratio
for MeiraGTx Holdings PLC.

Provide Current Ratio
for MeiraGTx Holdings PLC.

Provide Cash Ratio
for MeiraGTx Holdings PLC.

What is the historical Revenue growth
over the last 5 years for MeiraGTx Holdings PLC?

What is the historical Net Income growth
over the last 5 years for MeiraGTx Holdings PLC?

What is the current Free Cash Flow
of MeiraGTx Holdings PLC?

Discuss the annual earnings per share (EPS)
trend over the past five years for MeiraGTx Holdings PLC.

Financials

Balance Sheet Decomposition
MeiraGTx Holdings PLC

Current Assets 159.6m
Cash & Short-Term Investments 129.6m
Receivables 23.4m
Other Current Assets 6.6m
Non-Current Assets 167.1m
Long-Term Investments 6.8m
PP&E 156.2m
Intangibles 1.1m
Other Non-Current Assets 3m
Current Liabilities 67.1m
Accounts Payable 16m
Accrued Liabilities 46.8m
Other Current Liabilities 4.2m
Non-Current Liabilities 121.5m
Long-Term Debt 72.1m
Other Non-Current Liabilities 49.4m
Efficiency

Earnings Waterfall
MeiraGTx Holdings PLC

Revenue
14m USD
Operating Expenses
-151.1m USD
Operating Income
-137.1m USD
Other Expenses
53m USD
Net Income
-84m USD

Free Cash Flow Analysis
MeiraGTx Holdings PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

MGTX Profitability Score
Profitability Due Diligence

MeiraGTx Holdings PLC's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Negative 3-Years Revenue Growth
Negative 1-Year Revenue Growth
Declining ROIC
19/100
Profitability
Score

MeiraGTx Holdings PLC's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

MGTX Solvency Score
Solvency Due Diligence

MeiraGTx Holdings PLC's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Negative Net Debt
Long-Term Solvency
39/100
Solvency
Score

MeiraGTx Holdings PLC's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MGTX Price Targets Summary
MeiraGTx Holdings PLC

Wall Street analysts forecast MGTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MGTX is 22.03 USD with a low forecast of 11.11 USD and a high forecast of 37.8 USD.

Lowest
Price Target
11.11 USD
136% Upside
Average
Price Target
22.03 USD
368% Upside
Highest
Price Target
37.8 USD
703% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

MGTX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

MGTX Price
MeiraGTx Holdings PLC

1M 1M
-24%
6M 6M
+21%
1Y 1Y
-12%
3Y 3Y
-67%
5Y 5Y
-75%
10Y 10Y
-69%
Annual Price Range
4.71
52w Low
3.6
52w High
8.07
Price Metrics
Average Annual Return -9.79%
Standard Deviation of Annual Returns 51.2%
Max Drawdown -88%
Shares Statistics
Market Capitalization 299.6m USD
Shares Outstanding 64 217 200
Percentage of Shares Shorted 2.4%

MGTX Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

MeiraGTx Holdings PLC Logo
MeiraGTx Holdings PLC

Country

United States of America

Industry

Biotechnology

Market Cap

299.6m USD

Dividend Yield

0%

Description

MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. The company is headquartered in New York City, New York and currently employs 287 full-time employees. The company went IPO on 2018-06-08. The firm is focused on three areas of unmet medical needs, including inherited retinal diseases (IDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. The Company’s products pipeline includes AAV-RPGR, which is for the treatment of x-linked retinitis pigmentosa (XLRP); AAV-hAQP1, which is for the treatment of grade two/three radiation-induced xerostomia; AAV-GAD, is for the treatment of Parkinson’s disease, and AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia (ACHM). The firm has six programs in clinical development, including Phase I/Il clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa and RPE65-Deficiency, and Phase I clinical trials for radiation-induced xerostomia (RIX), and a Parkinson’s program that has completed a Phase II trial with published data.

Contact

NEW YORK
New York City
450 E 29th St Fl 15
+16464902965.0
http://meiragtx.com/

IPO

2018-06-08

Employees

287

Officers

CEO, President & Director
Dr. Alexandria Forbes Ph.D.
COO & CFO
Mr. Richard Brian Giroux B.A.
Chief Development Officer
Dr. Stuart Naylor Ph.D.
General Counsel & Secretary
Mr. Robert J. Wollin J.D.
Head of Clinical Ophthalmology
Dr. Michel Michaelides M.D.
Senior Vice President of Risk & Internal Controls
Mr. Tim Randall
Show More
Senior Vice President of Manufacturing & Supply Chain
Dr. Alastair Leighton Ph.D.
Chief Medical Officer
Dr. Robert K. Zeldin M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one MGTX stock?

The intrinsic value of one MGTX stock under the Base Case scenario is 45.8 USD.

Is MGTX stock undervalued or overvalued?

Compared to the current market price of 4.71 USD, MeiraGTx Holdings PLC is Undervalued by 90%.